The Efficacy of Danofloxacin in the Therapy of Acute Bacterial Pneumonia in Housed Beef Cattle

A Summary

Authors

  • S. T. Tolling Animal Health Group, Pfizer, Inc, New York, U.S.A.
  • H. Barthel Animal Health Division, Pfizer, Inc, Karlsruhe, Germany
  • C. J. Giles Central Research Division, Pfizer, Inc, Sandwich, U.K.
  • M. Isla Animal Health Division, Pfizer, Inc, Madrid, Spain
  • A. Mencarelli Animal Health Division, Pfizer, Inc, Rome, Italy
  • C. Thomasson European Clinical Development, Pfizer, Inc, Orsay, France

DOI:

https://doi.org/10.21423/aabppro19926452

Keywords:

Danofloxacin, respiratory disease, pharmacokinetic studies, acute pneumonia, oxytetracycline, trimethoprim/sulpha

Abstract

Danofloxacin* is an antimicrobial of the fluoroquinolone class, and has shown potent in vitro activity against the major bacterial pathogens involved in respiratory disease, Pasteurella haemolytica and Pasteurella multocida(1). Pharmacokinetic studies with danofloxacin in cattle have demonstrated an attractive profile. The drug is rapidly absorbed and distributed to respiratory tract tissues and secretions following intramuscular or subcutaneous administration ( 2, 3) . This paper summarizes the results of 11 studies in beef cattle conducted in Europe. The efficacy of danofloxacin against naturally occurring outbreaks of acute pneumonia was evaluated in comparison with oxytetracycline and trimethoprim/sulpha.

Spanish and French summaries on PDF.

Cover image of the First Volume of the 25th Conference Proceedings: An earl-morning photo of farmland. A small farm is nestled among rolling hills, fields stretching across a curving road that disappears between dark green trees. The barn is a cheery red color with a tin roof. Beneath the photo is the a statement of the conference's theme in white italics: Challenges of the Bovine Industry in the Twenty-First Century. Deep red background.

Downloads

Published

1992-08-31

Issue

1992: Volume 1

Section

Respiratory Disease / Immunology